I collect gold fingers in the heavens

Chapter 799 Broad Spectrum Anticancer Drugs

Among the anticancer drugs developed in this laboratory, one was developed for the purpose of broad-spectrum anticancer drugs.

The term [broad-spectrum] is easily reminiscent of broad-spectrum antibiotics.

[Broad-spectrum antibiotics] are drugs that can kill a variety of pathogenic microorganisms, such as [penicillin], which has a very brilliant record.

Someone once asked in the forum, if you bring a ton of [penicillin] back to those war-torn days, what will you get in return?
Ok.

There will be a [most reliable friend] evaluation.

And the treatment at Tiananmen Square.

indeed.

At that time, for many diseases, such as tuberculosis and other diseases, we all relied on this magic medicine.

With this magical medicine, how many soldiers' lives could be saved.

One can imagine how important this thing was in those days.

But [broad-spectrum anticancer drugs] are not [broad-spectrum antibiotics].

The so-called broad-spectrum anti-cancer refers to the effect on multiple different types of tumor targets.

However, if there is an effect, it is not necessarily a miracle. Some targets are more sensitive to the drug, and the curative effect is significant; some are not, and can only play a role in controlling the tumor from growing so fast or the condition from getting worse.

For example, [Vitrakvi], which was accelerated by the Food and Drug Administration of a certain country in 2018, is a so-called broad-spectrum anticancer drug.

The characteristic of this drug is that it does not consider the area where the cancer occurs, which is why it is labeled as "broad-spectrum". In essence, it is still a targeted drug. The targeted target is TRK. Adult and pediatric patients with locally advanced or metastatic solid tumors with gene fusions.

TRK fusion is a gene abnormality, which is the fusion of TRK gene and other genes. In this case, the proportion of common tumors is about 0.5% to 1%, but the proportion of some rare tumors can exceed 90%. Including salivary gland cancer, certain juvenile breast cancer, infantile fibrosarcoma, etc., TRK fusion will appear in the early stage of the tumor and persist during the growth and spread of the tumor.

The development of [Vitrakvi] is to focus on this TRK. It is essentially an oral TRK inhibitor that targets specific gene mutations rather than specific cancer types.

In clinical trials, [Vitrakvi] showed an objective response rate of 75%.

What does that mean?That is, no new lesions appear, and the tumor markers are normal for at least 4 weeks.

Among them, the complete remission rate was 22%.

However, the clinical cure referred to in medicine needs to achieve the target of no recurrence within 5 years.

Therefore, in terms of curative effect, this medicine is far from the imaginary realm of magic medicine.

[Vitrakvi] The specific explanation of the scope of application of the drug is as follows: there are no known acquired drug resistance mutations, metastatic disease or surgical resection may lead to serious complications, no satisfactory alternative treatment options or patients with progressive disease.

In human terms, if the patient has no other better treatment, try this.

…………………………………………………………………………………………………………………………………… ...........

No matter what anticancer drug is, the research and development process is full of hardships.

【Xuanhu Technology】The same is true for this broad-spectrum anticancer drug.

Researchers are screening PD-1 antibodies day and night to find PD-1 inhibitors, humanized monoclonal antibodies that block PD-1 receptor molecules.

The full name of PD-1 is programmed death receptor 1. After it binds to the ligand PD-L1, it will shut down the immune response of T cells, and T cells will not be able to find tumor cells and send attack signals to tumor cells.Immune regulation targeting PD-1 is of great significance in anti-tumor and anti-autoimmune diseases.

The mechanism of action of monoclonal antibodies against PD-1 and PD-L1 is actually that PD-1 and PD-L1 bind to each other, which can inhibit the activity of T cells, thereby inhibiting the effect of killing tumors.If the pathway is blocked in a targeted manner, T cells can be activated to achieve anti-tumor effects.

The research and development team of [Xuanhu Technology] is very lucky.

It didn't take them too much time to get results, and they successfully passed the animal experiment and the first phase of clinical experiment.

However, in the expanded trial of the second phase of clinical trials, the new drug developed by the R&D team of [Xuanhu Technology] has not achieved satisfactory results in terms of overall survival rate, objective response rate, disease control rate, clinical benefit rate and duration of response. .

To be precise, the effect is very unsatisfactory.

This means that this anticancer drug failed in human trials.

In fact, in the research and development of anticancer drugs, failure is normal, and success is accidental.

This is true whether it is a world-renowned large company or a small company.

Therefore, the development cost of anticancer drugs is very high.

It's too easy to lose sight of.

Many pharmaceutical companies in China are keen to make generic drugs, but not to research and develop new drugs.

Because if one is not done well, the company will develop a drug and face bankruptcy.

[Xuanhu Technology] There is a big boss who has a lot of money and is not interested in money, but only in influence.

That's why I dare to throw money like this!
Even if this research fails.

The senior management of [Xuanhu Technology] did not criticize anything, but let the team take a good rest and continue to work.

And the failed broad-spectrum anti-cancer drug was just shelved.

…………………………………………………………………………………………………………………………………… ...

Wu Siyuan asked for this [anticancer drug] by name.

He asked [Xuanhu Technology] to send relevant information to [Vision Company].

[Vision Company] has a laboratory in charge of He Youman himself.

Her team took over and re-researched this [cancer drug] and added certain things.

On the surface, some other small molecular compounds are added, but in fact, [nano medical particles] are filled in.

[Nanomedical Particles] are so small that they cannot be seen by the naked eye.

Even with a microscope, [Nanomedical Particles] can disguise themselves as small molecular compounds, which cannot be distinguished at all with the current technology of human beings.

After [feeding], this anti-cancer drug named [Redirimumab] started a new round of experiments.

There is no need for He Youman to do these basic tasks.

The research team of [Xuanhu Technology] was transferred out to do this kind of [rough work]!
Because of experience, it is easy to pass the first few levels. Animal experiments showed better experimental results, and then came to clinical experiments.

This made the research team of [Xuanhu Technology] very nervous.

Last time, they fell down here.

Moreover, the number of people in this experiment is larger than that of the clinical trials they conducted.

This is because [Super Group] attaches great importance to it, and Wu Siyuan attaches great importance to it.

The energy of [Superior Group] is of course not comparable to that of [Xuanhu Technology].

(End of this chapter)